Lung cancer biomarkers: present status and future developments.

Philip T. Cagle, Timothy Craig Allen, Randall J. Olsen

Research output: Contribution to journalReview article

36 Scopus citations

Abstract

The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.

Original languageEnglish (US)
Pages (from-to)1191-1198
Number of pages8
JournalUnknown Journal
Volume137
Issue number9
DOIs
StatePublished - Sep 2013

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Lung cancer biomarkers: present status and future developments.'. Together they form a unique fingerprint.

  • Cite this